BMEA — Expected Completion of Phase 2 Trial of BMF-219

Expected Completion of BMF-219 Clinical Trial

Biomea Fusion Inc. anticipates the completion of its clinical trial for BMF-219, a covalent menin inhibitor, on June 1, 2025. The Phase 1 trial is evaluating its efficacy in adult patients with various cancers, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) with specific mutations, diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL). Currently, the trial is active but not recruiting additional participants, having enrolled 55 patients since its start on January 24, 2022.

• www.clinicaltrials.gov/study/NCT05153330

Expected Completion of Phase 2A Clinical Trial for RAP-219

Rapport Therapeutics Inc. is expected to complete its Phase 2A clinical trial of RAP-219 for refractory focal epilepsy on June 1, 2025. This proof-of-concept study aims to evaluate the drug's efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic relationship in approximately 20 adult participants treated with the RNS® system. The trial is currently recruiting patients, with the trial's start date set for October 10, 2024. The completion of this trial could provide pivotal data for the future development of RAP-219 in addressing refractory focal epilepsy, a condition with significant unmet medical needs.

Expected Completion of Phase 2 Study of BA3021

BioAtla, Inc. is conducting a multi-center, open-label Phase 2 study of BA3021 to evaluate its efficacy and safety in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The expected completion date for this clinical trial is December 1, 2026, with an enrollment count of 290 patients. The study is currently in the recruiting phase and will assess BA3021 both as a monotherapy and in combination therapy. This trial's outcome could potentially impact treatment options for this patient population, relevant for investors assessing BioAtla's pipeline developments.

• www.clinicaltrials.gov/study/NCT05271604

Expected Completion of Phase 1/2 Clinical Trial for BDC-4182

Bolt Biotherapeutics, Inc. is expected to complete a Phase 1/2 clinical trial for BDC-4182, a drug aimed at treating advanced gastric and gastroesophageal cancer, on May 1, 2029. The study is a dose escalation trial designed to evaluate the safety and tolerability of BDC-4182 to establish the recommended Phase 2 dose. As of now, the trial is in the recruiting phase, with an enrollment count of 122 participants. The completion of this trial may significantly impact the company's pipeline and future product offerings.

• www.clinicaltrials.gov/study/NCT06921837